News

In light of the CTN clearance, Interius expects to initiate plans for a phase 1 clinical trial (INVISE) for INT2104 within the final quarter of 2024.

1x1015 vg 4D-710 has been identified as the maximum tolerated dose in the AEROW trial.

Review top news and interview highlights from the week ending July 12, 2024.

GT Biopharma anticipates initiating the phase 1 clinical trial in the second half of 2024.

The chairman and chief executive officer of NKGen discussed the new clinical study design for evaluating the NK cell therapy in PD.

Tr1X reported that the first patient has cleared the trial’s safety period successfully, having experienced no serious adverse events.

The PhD candidate from Lieden University Medical Center and Breakefield Lab at Mass Gen discussed her work presented at the ASGCT 2024 meeting.

The open-label, single-arm, multisite NEXICART-2 study will aim to enroll around 40 participants in total.

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Treated patients had a –0.2 mean change in cUHDRS compared with a –1.0 change in external control data.

The chairman and chief executive officer of NKGen discussed the mechanism behind the company’s NK cell therapy SNK01 and promising early results in patients with PD.

The professor of internal medicine and pediatrics at National Jewish Health discussed updated data from the phase 1/2 AEROW trial of 4D-710.

Ntrust-2 will assess NKX019 in systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.

The phase 1/2 GALILEO-1 trial has completed enrollment and a phase 3 trial is planned for 2025.

The Prescription Drug User Fee Act (PDUFA) target action date is August 4, 2024.

Deborah Phippard, PhD, the chief scientific officer of Precision for Medicine, discussed unique difficulties of designing clinical trials for PD gene therapy candidates.

The chairman and chief executive officer of NKGen discussed the potential of SNK01, the company’s autologous natural killer cell therapy, in treating PD.

Faraz Ali, MBA, the chief executive officer of Tenaya Therapeutics, discussed trends in precision medicine for cardiovascular indications.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

The trial's primary endpoint is improvement on Luminance Dependent Navigation Assessment (LDNA).

Review top news and interview highlights from the week ending July 5, 2024.

First-in-human data with low dose VRON-0200 were presented at the EASL 2024 congress.

The therapy, rAAV-Olig001-ASPA, has shown positive clinical benefits in several interim updates from an ongoing, first-in-human phase 1/2 clinical trial (NCT04833907).

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.